Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up
Jérôme Paillassa
(1)
,
Edouard Cornet
(2)
,
Stéphanie Noël
(3)
,
Cécile Tomowiak
(3)
,
Stéphane Lepretre
(4)
,
Sandrine Vaudaux
(4)
,
Jehan Dupuis
(5)
,
Alain Devidas
(6)
,
Bertrand Joly
(6)
,
Charlotte Petitdidier-Lionnet
(6)
,
Stéphanie Haiat
(6)
,
Clara Mariette
(7)
,
Catherine Thieblemont
(8)
,
Didier Decaudin
(9)
,
Patricia Validire-Charpy
(9)
,
Bernard Drenou
(10)
,
Jean-Claude Eisenmann
(10)
,
Mario Ojeda Uribe
(10)
,
Agnès Olivrie
(11)
,
Mohamed Touati
(11)
,
Olivier Lambotte
(12)
,
Olivier Hermine
(13)
,
Jean-Michel Karsenti
(14)
,
Pierre Feugier
(15)
,
Willy Vaillant
(16)
,
Jean Gutnecht
(17)
,
Eric Lippert
(18)
,
Fabienne Huysman
(19)
,
Kamel Ghomari
(19)
,
Marouane Boubaya
(20)
,
Vincent Levy
(20)
,
Jérémie Riou
(21)
,
Gandhi Damaj
(2)
,
Aline Schmidt
(22, 1, 23)
,
Mathilde Hunault-Berger
(22, 1, 23)
,
Xavier Troussard
(2)
1
CHU Angers -
Centre Hospitalier Universitaire d'Angers
2 CHU Caen
3 CIC - Poitiers
4 GPMCND - Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques
5 CHU Henri Mondor [Créteil]
6 CH Sud Francilien - Centre Hospitalier Sud Francilien [Corbeil-Essonnes]
7 CHU - Centre Hospitalier Universitaire [Grenoble]
8 AP-HP - Hopital Saint-Louis [AP-HP]
9 Institut Curie [Paris]
10 CH E.Muller Mulhouse - Centre Hospitalier Emile Muller [Mulhouse]
11 CHU Limoges
12 AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)
13 CHU Necker - Enfants Malades [AP-HP]
14 CHU Nice - Centre Hospitalier Universitaire de Nice
15 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
16 CH Auch - Centre Hospitalier d'Auch
17 CHI Fréjus - St Raphaël - Centre Hospitalier Intercommunal Fréjus - St Raphaël
18 CHU-Brest-Hemato - CHRU Brest - Service d'Hématologie
19 CH Beauvais
20 Hôpital Avicenne [AP-HP]
21 MINT - Micro et Nanomédecines Translationnelles
22 CRCINA-ÉQUIPE 7 - Innate Immunity and Immunotherapy
23 Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL)
2 CHU Caen
3 CIC - Poitiers
4 GPMCND - Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques
5 CHU Henri Mondor [Créteil]
6 CH Sud Francilien - Centre Hospitalier Sud Francilien [Corbeil-Essonnes]
7 CHU - Centre Hospitalier Universitaire [Grenoble]
8 AP-HP - Hopital Saint-Louis [AP-HP]
9 Institut Curie [Paris]
10 CH E.Muller Mulhouse - Centre Hospitalier Emile Muller [Mulhouse]
11 CHU Limoges
12 AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)
13 CHU Necker - Enfants Malades [AP-HP]
14 CHU Nice - Centre Hospitalier Universitaire de Nice
15 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
16 CH Auch - Centre Hospitalier d'Auch
17 CHI Fréjus - St Raphaël - Centre Hospitalier Intercommunal Fréjus - St Raphaël
18 CHU-Brest-Hemato - CHRU Brest - Service d'Hématologie
19 CH Beauvais
20 Hôpital Avicenne [AP-HP]
21 MINT - Micro et Nanomédecines Translationnelles
22 CRCINA-ÉQUIPE 7 - Innate Immunity and Immunotherapy
23 Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL)
Edouard Cornet
- Function : Author
- PersonId : 791858
- ORCID : 0000-0003-1667-3421
- IdRef : 139775110
Olivier Hermine
- Function : Author
- PersonId : 756140
- ORCID : 0000-0003-2574-3874
- IdRef : 069884927
Aline Schmidt
- Function : Author
- PersonId : 749561
- IdHAL : aline-schmidt
- ORCID : 0000-0003-0278-7479
Mathilde Hunault-Berger
- Function : Author
- PersonId : 752203
- IdHAL : mathilde-hunault-berger
- ORCID : 0000-0001-7777-5216
Xavier Troussard
Connectez-vous pour contacter l'auteur
- Function : Correspondent author
- PersonId : 855408
Connectez-vous pour contacter l'auteur
Abstract
Abstract In total, 279 patients with hairy-cell leukemia (HCL) were analyzed, with a median follow-up of 10 years. Data were collected up to June 2018. We analyzed responses to treatment, relapses, survival, and the occurrence of second malignancies during follow-up. The median age was 59 years. In total, 208 patients (75%) were treated with purine analogs (PNAs), either cladribine (159) or pentosatin (49), as the first-line therapy. After a median follow-up of 127 months, the median overall survival was 27 years, and the median relapse-free survival (RFS) was 11 years. The cumulative 10-year relapse incidence was 39%. In patients receiving second-line therapy, the median RFS was 7 years. For the second-line therapy, using the same or another PNA was equivalent. We identified 68 second malignancies in 59 patients: 49 solid cancers and 19 hematological malignancies. The 10-year cumulative incidences of cancers, solid tumors, and hematological malignancies were 15%, 11%, and 5.0%, respectively, and the standardized incidence ratios were 2.22, 1.81, and 6.67, respectively. In multivariate analysis, PNA was not a risk factor for second malignancies. HCL patients have a good long-term prognosis. PNAs are the first-line treatment. HCL patients require long-term follow-up because of their relatively increased risk of second malignancies.
Domains
Cancer
Origin : Publication funded by an institution